AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Canada Pension Plan Investment Board purchased a new position in shares of AngioDynamics, Inc. (NASDAQ: ANGO) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 32,900 shares of the medical instruments supplier's stock, valued at approximately $428,000. Canada Pension Plan
Bank of America Corp DE grew its holdings in shares of AngioDynamics, Inc. (NASDAQ: ANGO) by 262.7% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 503,640 shares of the medical instruments supplier's stock after purchasing an additional 364,763
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?
AngioDynamics NASDAQ: ANGO expects its MedTech business to become the majority of company revenue in fiscal 2027, as the company continues a multiyear shift away from slower-growth legacy markets and toward higher-growth medical technology platforms, executives said during a Canaccord fireside chat.
AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.
Canada Pension Plan Investment Board purchased a new position in shares of AngioDynamics, Inc. (NASDAQ: ANGO) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 32,900 shares of the medical instruments supplier's stock, valued at approximately $428,000. Canada Pension Plan
Bank of America Corp DE grew its holdings in shares of AngioDynamics, Inc. (NASDAQ: ANGO) by 262.7% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 503,640 shares of the medical instruments supplier's stock after purchasing an additional 364,763
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?
AngioDynamics NASDAQ: ANGO expects its MedTech business to become the majority of company revenue in fiscal 2027, as the company continues a multiyear shift away from slower-growth legacy markets and toward higher-growth medical technology platforms, executives said during a Canaccord fireside chat.
AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.
AngioDynamics' fiscal 2027 outlook hinges on Med Tech growth offsetting flat device sales as tariffs, spending and losses pressure margins.
AngioDynamics' 33.5% three-month rally rests on Med Tech growth, but valuation, tariffs and negative earnings keep execution risks high.
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular syste
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its management team is scheduled to participate in the following upcoming investor conferences: 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference Monday, August 10, 2026 Canaccord Genuity's 4.
AngioDynamics develops tools for minimally invasive procedures across blood flow, blocked arteries, and prostate cancer treatment. Key offerings include AlphaVac and AngioVac for clot removal, Auryon for arterial plaque, and NanoKnife for prostate cancer. After a prolonged period of stagnation, ANGO shares are finally showing signs of positive momentum.
ANGO's Q4 FY26 revenues rise 8% as Med Tech surges, while its adjusted loss beats estimates and FY27 sales guidance tops consensus.
AngioDynamics, Inc. (ANGO) Q4 2026 Earnings Call Transcript
AngioDynamics NASDAQ: ANGO reported higher fiscal fourth-quarter and full-year revenue, driven by continued growth in its med tech portfolio, while management said the company remains focused on balancing investment in clinical programs with profitability and cash generation.
AngioDynamics (ANGO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.03 per share a year ago.
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2026, which ended May 31, 2026. Fiscal Year 2026 Fourth Quarter Financial Highlights Quarter Ended May 31, 2026 Pro Forma* YoY Growth Pro Forma* N.
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the fourth quarter and full year of fiscal year 2026 before the market open on Tuesday, July 14, 2026. The Company's management will host a conference call at 8:00 am ET the same day to discuss the re.
ANGO's NanoKnife growth, strong Med Tech momentum and solid Q3 results support holding the stock despite tariff and inflation pressures.
AngioDynamics' FDA IDE approval for RELIEF advances NanoKnife IRE study as a potential minimally invasive BPH treatment.
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational Device Exemption (IDE) application to initiate the RELIEF study. RELIEF is a feasibility study evaluating irreversible electroporation (IRE), the non-.
AngioDynamics, Inc. (ANGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
